DETERMINE trial aims to discover if current treatments could benefit patients with other cancer types More: Novartis joins Cancer Research UK on rare cancers study Source: News
read moreASH: Bristol’s third-line Abecma data didn’t make the trip to New Orleans. Is it cause for concern? aliu Mon, 12/12/2022 – 16:20 More: ASH: Bristol's third-line Abecma data didn't make the trip to New Orleans. Is it cause for concern?
read moreASH: CSL, uniQure’s gene therapy Hemgenix shows durable protection in hemophilia B kdunleavy Mon, 12/12/2022 – 14:25 More: ASH: CSL, uniQure's gene therapy Hemgenix shows durable protection in hemophilia B Source: fierce
read moreSanofi started—and lost—$28B bidding war for Horizon. Is the company’s M&A appetite still rumbling? fkansteiner Mon, 12/12/2022 – 13:57 More: Sanofi started—and lost—B bidding war for Horizon. Is the company's M&A appetite still rumbling? Source: fierce
read moreClovis Oncology finally throws in the towel, files for bankruptcy zbecker Mon, 12/12/2022 – 11:34 More: Clovis Oncology finally throws in the towel, files for bankruptcy Source: fierce
read moreAstraZeneca, Biogen, Daiichi, Lundbeck, UCB all hit with drug marketing breaches, but highest censure reserved for Novo Nordisk badams Mon, 12/12/2022 – 11:30 More: AstraZeneca, Biogen, Daiichi, Lundbeck, UCB all hit with drug marketing breaches, but highest censure reserved for
read more© 1994 - 2026 B.M. Pharmaceuticals